Capromorelin: A Literature Course on What the Published Studies Report

Capromorelin is a small-molecule ghrelin receptor agonist that appears in the published literature mainly as an orally administered appetite stimulant in veterinary species, and in one early-phase human safety and pharmacokinetic trial conducted in spinal cord-injured and able-bodied volunteers (PMID 25448190). This course walks through the evidence base in six modules and closes with what the studies did not test. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medicines or research participation. Nothing here is a protocol, a recommendation, or a statement of benefit.

Module 1 — What Capromorelin Is and How It Has Been Studied

Definition and class

Capromorelin is described in the literature as an orally active, non-peptide growth hormone secretagogue that acts as an agonist at the ghrelin receptor (growth hormone secretagogue receptor type 1a, GHS-R1a). Although it is often grouped with research peptides because it mimics the action of the peptide hormone ghrelin, it is not itself a peptide: a 2018 overview characterised capromorelin as a ghrelin receptor agonist developed as a therapy for stimulation of appetite in dogs (PMID 29468076). A 2024 veterinary review summarised its discovery, efficacy, safety and clinical applications in veterinary medicine (PMID 37493940).

Origin and chemical lineage

Capromorelin emerged from medicinal-chemistry programmes aimed at orally bioavailable growth hormone secretagogues. A 2002 report described the discovery and biological characterisation of capromorelin analogues with extended half-lives, indicating that the molecule served as a chemical starting point for further secretagogue design (PMID 12392732).

Forms and routes that have been studied

• Oral solution: a randomised, masked, placebo-controlled study administered capromorelin oral solution to healthy adult Beagle dogs for four consecutive days (PMID 28056951).
• Enteral administration in rodents: researchers investigated the effect of enterally administered capromorelin on body weight in mice (PMID 39025662).
• Oral and dermal exposure: a 2023 analytical study examined detection of capromorelin in urine following oral and dermal routes of administration (PMID 37688359).
• Single oral doses in humans: a Phase-I single ascending dose trial assessed safety and pharmacokinetics in spinal cord-injured and able-bodied volunteers (PMID 25448190).

Limits of the evidence in Module 1

The literature that defines capromorelin is dominated by veterinary and laboratory-animal work. There is no large published human clinical programme, no long-term human outcome data, and no published head-to-head comparison across all of the species studied. Descriptions of chemical class and receptor target are consistent, but the depth of characterisation differs sharply between dogs and cats on one hand and other species on the other.

Module 2 — Mechanism as Described in the Literature

Papers on capromorelin consistently describe a two-branch mechanism that follows from GHS-R1a agonism. First, the receptor is expressed in the anterior pituitary, where ghrelin-mimetic signalling is linked to growth hormone release; second, it is expressed in hypothalamic circuits associated with hunger signalling. The 2024 veterinary review framed capromorelin as a ghrelin receptor agonist whose appetite-stimulating and growth hormone-related actions underpin its veterinary applications (PMID 37493940), and the 2018 dog-focused overview described appetite stimulation as the intended pharmacological consequence of ghrelin receptor agonism (PMID 29468076).

Because growth hormone influences glucose handling, several groups asked whether a ghrelin receptor agonist measurably shifts glucose metabolism. Researchers examined the effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats (PMID 32619812), and a separate 2022 study examined the effect of capromorelin on glycemic control in healthy dogs (PMID 35689953). Both were designed around metabolic endpoints rather than appetite endpoints, which makes them the clearest mechanistic probes in the animal literature.

Limits of the evidence in Module 2

Mechanism in these papers is largely inferred from receptor pharmacology and from downstream hormone or glucose measurements, not from human tissue-level experiments. Species differences in ghrelin receptor distribution and in growth hormone dynamics mean a mechanism demonstrated in one species cannot be assumed to operate identically in another. No verified paper here maps capromorelin's mechanism in human hypothalamic circuits.

Module 3 — Reported Outcomes, Study by Study

The table below lists the models, designs and reported directions of effect. It is a summary of what researchers measured and published; it is not a statement that any outcome would occur in any individual.

Two features of this evidence base stand out. First, the strongest designs — randomised, masked and placebo-controlled — sit in companion-animal work: the four-day Beagle study (PMID 28056951) and the feline weight-loss trial (PMID 41204815). Second, the laboratory-animal literature in mice, rabbits and macaques was largely motivated by whether an appetite stimulant could support animals in research or clinical care settings, with body weight, food intake and tolerability as endpoints (PMID 39025662, PMID 35981857, PMID 38423529).

Limits of the evidence in Module 3

Most studies were short, used small numbers of animals, and measured surrogate endpoints such as food consumption or short-term weight change rather than survival, function or quality of life. Healthy-animal studies cannot be extrapolated to disease states, and species-specific dosing and formulation differences mean results do not transfer between species. No verified study reported human appetite or human body-weight outcomes.

Module 4 — Capromorelin Side Effects: What Studies Report

Adverse-event reporting for capromorelin is concentrated in the veterinary and laboratory-animal literature, where tolerability was usually a co-primary consideration alongside appetite or weight endpoints.

• Gastrointestinal and salivation signs. The 2024 veterinary review of capromorelin's discovery, efficacy, safety and clinical applications discussed the adverse effects described across veterinary use, with transient gastrointestinal signs such as vomiting, hypersalivation and loose stools among the events characterised in that literature (PMID 37493940). The randomised, masked, placebo-controlled Beagle study that administered capromorelin oral solution for 4 consecutive days also recorded tolerability alongside its food-consumption and body-weight endpoints (PMID 28056951).
• Glucose-related changes. Because growth hormone secretagogues can influence glucose handling, researchers specifically examined capromorelin's effect on glycemic control in healthy dogs (PMID 35689953) and on glucose metabolism in healthy cats (PMID 32619812). These papers are the appropriate reference points for anyone reading about metabolic effects, since they were designed to measure them rather than to detect them incidentally.
• Non-human primate safety. A 2024 study evaluated both the safety and the efficacy of capromorelin in rhesus macaques, making tolerability an explicit endpoint in that species (PMID 38423529).
• Human single-dose safety. The Phase-I single ascending dose trial in spinal cord-injured and able-bodied volunteers was designed as a safety and pharmacokinetic study, meaning human adverse-event data exist only for single escalating oral doses in a small volunteer population (PMID 25448190).

Limits of the evidence in Module 4

Adverse-event data are short-term and species-specific. Rare events, delayed events and interactions with other medicines would not be detectable in studies of this size and duration, and no verified paper reported repeated-dose human safety over weeks or months. Absence of a reported adverse event in a small study is not evidence that the event does not occur.

Module 5 — Pharmacokinetics Where Data Exist

Human pharmacokinetic data come from a single published source. The Phase-I single ascending dose trial characterised the pharmacokinetics of the ghrelin agonist capromorelin in spinal cord-injured and able-bodied volunteers, comparing exposure between those two groups within a safety framework (PMID 25448190). That design answers questions about single-dose exposure and short-term tolerability; it does not describe steady-state kinetics, accumulation or dose-proportionality over prolonged administration.

Two other papers bear on disposition indirectly. The 2002 medicinal-chemistry report described capromorelin analogues with extended half-lives, which implies that half-life was a recognised design constraint for the parent molecule (PMID 12392732). Separately, a 2023 analytical study examined detection of capromorelin in urine following oral and dermal routes of administration, addressing how long and by what route the compound and its markers can be identified in urine (PMID 37688359). The dermal arm is notable because it speaks to inadvertent exposure and to analytical interpretation, not to intended use.

In animals, exposure has been studied alongside formulation. The oral solution used in the four-day randomised Beagle study was the dosage form that later became the basis of veterinary product development (PMID 28056951), and enteral delivery was specifically chosen for the mouse body-weight study (PMID 39025662).

Limits of the evidence in Module 5

There is no published human multiple-dose pharmacokinetic study in the verified set, no human tissue-distribution or metabolite-profiling paper, and no comparison of human and animal exposure at matched doses. Urine-detection windows described for analytical purposes are not pharmacokinetic parameters and should not be read as such.

Module 6 — Regulatory Status, Stated Factually

Capromorelin's regulatory identity is unusual: it is an approved animal drug and an unapproved human drug.

1. Approved veterinary products. Capromorelin oral solution is marketed in the United States as a US Food and Drug Administration-approved animal drug for appetite stimulation in dogs; the brand name ENTYCE appears in the title of the randomised, masked, placebo-controlled Beagle study that reported increased food consumption and body weight over 4 consecutive days of administration (PMID 28056951). A separate capromorelin oral solution is approved for management of weight loss in cats with chronic kidney disease, and the feline literature includes a randomised, masked, placebo-controlled trial reporting weight gain in cats with unintended weight loss (PMID 41204815). The 2024 review summarised these clinical applications within veterinary medicine (PMID 37493940).
2. Human status. Capromorelin is not an approved human medicine in the United States or the European Union. Human exposure in the verified literature is limited to the Phase-I single ascending dose safety and pharmacokinetic trial (PMID 25448190).
3. Research-use-only material. Chemical suppliers commonly label capromorelin "for research use only, not for human consumption." That label is a legal designation describing the intended market of the material; it is not an approval, a quality standard, or an indication that human administration has been evaluated.
4. Compounding. In the United States, compounding of human drugs from bulk substances under section 503A/503B is restricted to substances that are components of approved drugs or that appear on FDA bulk-substance lists; capromorelin is not an approved human drug ingredient. Compounding of animal drugs from bulk substances is likewise limited under FDA guidance for industry on compounding animal drugs, with approved products such as the capromorelin oral solutions described in the veterinary literature being the default (PMID 37493940).
5. Sport and anti-doping context. Growth hormone secretagogues are prohibited in regulated sport, which is the practical reason analytical chemists published methods for detecting capromorelin in urine after oral and dermal administration (PMID 37688359).

This is general regulatory information, not legal advice; rules differ by country, state and profession and change over time.

Limits of the evidence in Module 6

Regulatory status is jurisdictional and time-sensitive, and published papers describe the science rather than current statutory text. Approval for a veterinary indication says nothing about human safety, human efficacy or the quality of unapproved material sold under a research-use label.

What the Studies Did Not Test

Reading the verified literature as a whole, several gaps are explicit:

• Human efficacy. No verified study reported appetite, lean mass, strength, body-composition or functional outcomes in humans; human data are confined to single-dose safety and pharmacokinetics (PMID 25448190).
• Long-term administration. The randomised dog study covered 4 consecutive days (PMID 28056951), and no verified paper reported multi-year use in any species.
• Metabolic outcomes in disease. Glucose endpoints were studied in healthy dogs (PMID 35689953) and healthy cats (PMID 32619812), not in animals with diabetes.
• Combinations. Only one comparison against another appetite-modifying drug appears here, capromorelin versus mirtazapine in rabbits, and it was a comparison rather than a combination study (PMID 35981857).
• Injectable use. The verified literature covers oral, enteral and dermal exposure routes (PMID 39025662, PMID 37688359); none of these papers evaluated injected capromorelin in humans.
• Special populations. No verified paper examined pregnancy, paediatric populations, hepatic or renal impairment in humans, or drug–drug interactions.

The honest summary is that capromorelin is a well-characterised veterinary appetite stimulant with a single published early-phase human pharmacokinetic and safety trial. Anything beyond that — including how it might behave with repeated human dosing — is not answered by the studies above. This page is educational only and is not medical advice; questions about health should be directed to a licensed physician.

References

• Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs (Veterinary Medicine and Science, 2018)
• Capromorelin oral solution (ENTYCE) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study (BMC Veterinary Research, 2017)
• Insights on discovery, efficacy, safety and clinical applications of ghrelin receptor agonist capromorelin in veterinary medicine (Veterinary Research Communications, 2024)
• Capromorelin promotes weight gain in cats with unintended weight loss: a randomized, masked, placebo-controlled clinical trial (Journal of Feline Medicine and Surgery, 2025)
• The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats (Domestic Animal Endocrinology, 2021)
• The effect of capromorelin on glycemic control in healthy dogs (Domestic Animal Endocrinology, 2022)
• Comparison of Effects of Capromorelin and Mirtazapine on Appetite in New Zealand White Rabbits (JAALAS, 2022)
• Investigating the Effect of Enterally Administered Capromorelin on Body Weight in Mice (Comparative Medicine, 2024)
• Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (JAALAS, 2024)
• Pharmacokinetics of the ghrelin agonist capromorelin in a single ascending dose Phase-I safety trial in spinal cord-injured and able-bodied volunteers (Spinal Cord, 2015)
• Detection of capromorelin in urine following oral and dermal routes of administration (Drug Testing and Analysis, 2023)
• Discovery and biological characterization of capromorelin analogues with extended half-lives (Bioorganic & Medicinal Chemistry Letters, 2002)